Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Anish K Simhal, Kylee H Maclachlan, Rena Elkin, Jiening Zhu, Larry Norton, Joseph O Deasy, Jung Hun Oh, Saad Z Usmani, Allen Tannenbaum
The plasma cell cancer multiple myeloma (MM) varies significantly in genomic characteristics, response to therapy, and long-term prognosis. To investigate global interactions in MM, we combined a known protein interaction network with a large clinically annotated MM dataset. We hypothesized that an unbiased network analysis method based on large-scale similarities in gene expression, copy number aberration, and protein interactions may provide novel biological insights. Applying a novel measure of network robustness, Ollivier-Ricci Curvature, we examined patterns in the RNA-Seq gene expression and CNA data and how they relate to clinical outcomes...
November 30, 2023: Blood Cancer Journal
#2
Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He, Haojie Dong, Yuhui Wu, Hanying Wang, Zheng Li, Brian Ball, Samer Khaled, Guido Marcucci, Ling Li
No abstract text is available yet for this article.
November 28, 2023: Blood Cancer Journal
#3
JOURNAL ARTICLE
Yue Yang, Salar Abbas, Mohammad A Sayem, Avik Dutta, Golam Mohi
SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofibrosis (MF). However, the contribution of SRSF2 mutation in JAK2V617F-driven MPN remains elusive. To investigate the consequences of SRSF2P95H and JAK2V617F mutations in MPN, we generated Cre-inducible Srsf2P95H/+ Jak2V617F/+ knock-in mice. We show that co-expression of Srsf2P95H mutant reduced red blood cell, neutrophil, and platelet counts, attenuated splenomegaly but did not induce bone marrow fibrosis in Jak2V617F/+ mice...
November 27, 2023: Blood Cancer Journal
#4
LETTER
Miao Wang, Han-Yu Cao, Kai-Wen Tan, Qiao-Cheng Qiu, Yuan-Hong Huang, Shuai-Shuai Ge, Zi-Hao Wang, Jia Chen, Xiao-Wen Tang, De-Pei Wu, Sheng-Li Xue, Zheng Li, Hai-Ping Dai
No abstract text is available yet for this article.
November 27, 2023: Blood Cancer Journal
#5
LETTER
Rajshekhar Chakraborty, Divaya Bhutani, Mathew S Maurer, Meera Mohan, Suzanne Lentzsch, Anita D'Souza
No abstract text is available yet for this article.
November 27, 2023: Blood Cancer Journal
#6
LETTER
Susan Bal, Noel Estrada-Merly, Luciano J Costa, Muzaffar H Qazilbash, Shaji Kumar, Anita D'Souza
No abstract text is available yet for this article.
November 15, 2023: Blood Cancer Journal
#7
LETTER
Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Yiqing Li, Zhenqian Huang, Qixin Sun, Changfen Huang, Xiaqi Nie, Zurong Yao, Pengcheng Shi, Yu Zhang, Xuejie Jiang, Qifa Liu, Guopan Yu
No abstract text is available yet for this article.
November 13, 2023: Blood Cancer Journal
#8
JOURNAL ARTICLE
Allison M Bock, Jennifer J Gile, Melissa C Larson, Kittika Poonsombudlert, Reema K Tawfiq, Seth Maliske, Matthew J Maurer, Brian F Kabat, Jonas Paludo, David J Inwards, Sabarish Ayyappan, Brian K Link, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Grzegorz S Nowakowski, James R Cerhan, Umar Farooq, Yucai Wang
Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003-2009 (Era 1), 2010-2014 (Era 2), and 2015-2021 (Era 3)...
November 13, 2023: Blood Cancer Journal
#9
LETTER
Michael Ozga, Qiuhong Zhao, Laila Huric, Cecelia Miller, Ashley Rosko, Abdullah Khan, Elvira Umyarova, Don Benson, Francesca Cottini
No abstract text is available yet for this article.
November 10, 2023: Blood Cancer Journal
#10
EDITORIAL
Hira Mian, Tanya M Wildes, Christopher P Venner, Rafael Fonseca
No abstract text is available yet for this article.
November 8, 2023: Blood Cancer Journal
#11
LETTER
Hiroki Mizumaki, Dung Cao Tran, Kohei Hosokawa, Kazuyoshi Hosomichi, Yoshitaka Zaimoku, Hiroyuki Takamatsu, Hirohito Yamazaki, Ken Ishiyama, Rena Yamazaki, Hiroshi Fujiwara, Atsushi Tajima, Shinji Nakao
No abstract text is available yet for this article.
November 8, 2023: Blood Cancer Journal
#12
LETTER
Margherita Vieri, Vithurithra Tharmapalan, Milena Kalmer, Julian Baumeister, Miloš Nikolić, Matthis Schnitker, Martin Kirschner, Niclas Flosdorf, Marcelo A S de Toledo, Martin Zenke, Steffen Koschmieder, Tim H Brümmendorf, Fabian Beier, Wolfgang Wagner
No abstract text is available yet for this article.
November 6, 2023: Blood Cancer Journal
#13
LETTER
Rahul Banerjee, Bo Wang, Larry D Anderson, Georgia McCaughan, Nikita Mehra, Andrew J Cowan, S Vincent Rajkumar, Gurbakhash Kaur
No abstract text is available yet for this article.
November 6, 2023: Blood Cancer Journal
#14
LETTER
Melanie Klausner, Brian Phan, Laura Morsberger, Rebecca Parish, Alison Shane, Rebecca Park, Christopher D Gocke, Rena R Xian, Rick John Jones, Javier Bolaños-Meade, Lukasz P Gondek, Michael Phan, Ying S Zou
No abstract text is available yet for this article.
November 6, 2023: Blood Cancer Journal
#15
LETTER
Maja Ludvigsen, Amanda Jessica Campbell, Marie Beck Enemark, Trine Engelbrecht Hybel, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Bjerre, Lars Møller Pedersen, Harald Holte, Sirpa Leppä, Judit Meszaros Jørgensen, Bent Honoré
No abstract text is available yet for this article.
October 26, 2023: Blood Cancer Journal
#16
LETTER
Anaïs Schavgoulidze, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Lydia Montes, Caroline Jacquet, Karim Belhadj, Sabine Brechignac, Laurent Frenzel, Thomas Chalopin, Philippe Rey, Jean-Marc Schiano de Collela, Mamoun Dib, Denis Caillot, Margaret Macro, Jean Fontan, Laure Buisson, Luka Pavageau, Murielle Roussel, Salomon Manier, Mohamad Mohty, Ludovic Martinet, Hervé Avet-Loiseau, Jill Corre
No abstract text is available yet for this article.
October 26, 2023: Blood Cancer Journal
#17
EDITORIAL
Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel G M Olde Rikkert, Richard Horton, Robert Mash, Carlos Monteiro, Elena N Naumova, Eric J Rubin, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski, Arun Mitra, Tilman Ruff, Andy Haines, Ira Helfand
No abstract text is available yet for this article.
October 18, 2023: Blood Cancer Journal
#18
LETTER
Surbhi Sidana, Hitomi Hosoya, Alexandria Jensen, Lawrence Liu, Anmol Goyal, Vanna Hovanky, Bita Sahaf, Sushma Bharadwaj, Theresa Latchford, Sally Arai, Sheryl Leahy, Matthew Mei, Lihua E Budde, Lori S Muffly, Matthew J Frank, Saurabh Dahiya, Myo Htut, David Miklos, Murali Janakiram
No abstract text is available yet for this article.
October 13, 2023: Blood Cancer Journal
#19
JOURNAL ARTICLE
Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen
Currently, the International Prognostic Index (IPI) is the most used and reported model for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). IPI-like variations have been proposed, but only a few have been validated in different populations (e.g., revised IPI (R-IPI), National Comprehensive Cancer Network IPI (NCCN-IPI)). We aimed to validate and compare different IPI-like variations to identify the model with the highest predictive accuracy for survival in newly diagnosed DLBCL patients...
October 13, 2023: Blood Cancer Journal
#20
LETTER
Preetesh Jain, Krystle Nomie, Nikita Kotlov, VitaIy Segodin, Holly Hill, Chi Young Ok, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Francisco Vega, Alexander Bagaev, Nathan Fowler, Christopher R Flowers, Michael Wang
No abstract text is available yet for this article.
October 12, 2023: Blood Cancer Journal
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
